Evaluation of cardiovascular risk in a lung cancer screening cohort

ThoraxSep 30, 2019

Ruparel M, Quaife SL, Dickson JL, et al. - Among lung cancer screening (LCS) participants in the Lung Screen Uptake Trial, researchers investigated the benefit of coronary artery calcification (CAC) and cardiovascular disease (CVD) risk evaluation in this cross-sectional analysis. Participants (n = 680) aged 60–75 years and were current and ex-smokers. The presence of CAC was noted in 421 (61.9%) and in 49 (7.2%), this was heavy. A QRISK2 ≥ 10% was seen in 668 (98%) of participants, and a positive link of QRISK2 with increasing CAC grade was evident. A history of statin use was not reported by 56.8% of those who qualified for statin primary prevention (QRISK2 ≥ 10%). The link of statin use with age, body mass index and history of hypertension and diabetes was revealed in the multivariate analysis. In all LCS participants, CVD risk evaluation may be done along with LCS, regardless of the presence of low-dose computed tomography-detected CAC.

Whether it's latest news or articles from 1000+ journals, M3 India is a one-stop platform for Indian Doctors. You can browse curated content, access market research opportunities and use our proprietary communication tools to collaborate with Pharma and Healthcare businesses.